通心络胶囊联合瑞舒伐他汀治疗颈动脉粥样硬化的系统评价  

Systematic evaluation of Tongxinluo capsule combined with rosuvastatin in the treatment of carotid atherosclerosis

作　　者：刘伟 李星星 林泉 范宗静[1] 崔杰[1] 吴旸[1] LIU Wei;LI Xingxing;LIN Quan;FAN Zongjing;CUI Jie;WU Yang(Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;The Hospital Affiliated to Shaanxi University of Chinese Medicine,Xianyang,Shaanxi 712000,China)

机构地区：[1]北京中医药大学东方医院,北京市100078 [2]陕西中医药大学附属医院,陕西省咸阳市712000

出　　处：《中国动脉硬化杂志》2024年第12期1074-1081,共8页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金项目(81573900);中央高校基本科研业务费专项资金项目(2022-JYB-XJSJJ-073);北京中医药大学新奥奖励基金项目(2019-XAJLJJ-019)。

摘　　要：[目的]系统评价通心络胶囊联合瑞舒伐他汀治疗颈动脉粥样硬化的有效性和安全性。[方法]通过网络检索中国知网数据库、万方数据库、维普数据库、PubMed、Embase、The Cochrane Library、Web of Science,检索时间从建库至2023年8月31日,全面筛选通心络胶囊联合瑞舒伐他汀治疗颈动脉粥样硬化的随机对照研究文献,使用RevMan 5.4软件进行Meta分析。[结果]共纳入8项研究,总病例数858例,治疗组426例,对照组432例。Meta分析结果显示,在瑞舒伐他汀治疗的基础上加用通心络胶囊能降低总胆固醇(MD=-0.54,95%CI:-0.61~-0.46,P<0.00001)、甘油三酯(MD=-0.28,95%CI:-0.37~-0.20,P<0.00001)、低密度脂蛋白胆固醇(MD=-0.35,95%CI:-0.42~-0.29,P<0.00001)和升高高密度脂蛋白胆固醇(MD=0.27,95%CI:0.05~0.50,P=0.02)水平,降低颈动脉内膜中膜厚度(MD=-0.35,95%CI:-0.48~-0.22,P<0.00001)和斑块Crouse积分(MD=-1.33,95%CI:-2.11~-0.55,P=0.0009),差异均有统计学意义(P<0.05)。5项研究报道了不良反应情况,差异无统计学意义(MD=1.80,95%CI:0.80~4.08,P=0.16)。[结论]通心络胶囊联合瑞舒伐他汀治疗颈动脉粥样硬化能改善血脂水平并减轻动脉粥样硬化程度,疗效和安全性均较好,可在临床进一步推广使用。Aim To systematically evaluate the efficacy and safety of Tongxinluo capsule combined with rosuvastatin in the treatment of carotid atherosclerosis.Methods A comprehensive screening of Tongxinluo capsule combined with rosuvastatin was performed by Web searching the CNKI,Wanfang Data,VIP,PubMed,Embase,The Cochrane Library,and Web of Science from the construction of the database to August 31,2023,to comprehensively screen the literature of randomized controlled studies of Tongxinluo capsule combined with rosuvastatin in the treatment of carotid atherosclerosis in the literature of randomized controlled studies,and Meta-analysis was performed using RevMan 5.4 software.Results A total of 8 studies were included with 858 total cases,426 in the treatment group and 432 in the control group.Meta-analysis showed that the addition of Tongxinluo capsule to rosuvastatin treatment lowered total cholesterol(MD=-0.54,95%CI:-0.61~-0.46,P<0.00001),triglyceride(MD=-0.28,95%CI:-0.37~-0.20,P<0.00001),low density lipoprotein cholesterol(MD=-0.35,95%CI:-0.42~-0.29,P<0.00001)and increased high density lipoprotein cholesterol(MD=0.27,95%CI:0.05~0.50,P=0.02)levels,lowered carotid intima-media thickness(MD=-0.35,95%CI:-0.48~-0.22,P<0.00001)and plaque Crouse s score(MD=-1.33,95%CI:-2.11~-0.55,P=0.0009),and the differences were statistically significant(P<0.05).Adverse effects were reported in five studies,and the difference was not statistically significant(MD=1.80,95%CI:0.80~4.08,P=0.16).Conclusion Tongxinluo capsule combined with rosuvastatin in the treatment of carotid atherosclerosis can improve the blood lipid level and reduce the degree of atherosclerosis,with better efficacy and safety,which can be further promoted for clinical use.

关 键 词：通心络胶囊 瑞舒伐他汀 系统评价 META分析 随机对照试验 

分 类 号：R5[医药卫生—内科学] R28[医药卫生—临床医学]